Edgewise Therapeutics (EWTX) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Edgewise Therapeutics (EWTX) over the past year, gaining 226.6% versus a gain of 155.6%. Over five years, EWTX leads with a +121.1% price change compared with +60.9% for TNGX. Edgewise Therapeutics is the larger company by market cap ($4.26 billion vs $3.81 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | TNGX |
|---|---|---|
| Share price | $39.23 | $22.57 |
| Market cap | $4.26B | $3.81B |
| 1-day change | -0.86% | +3.39% |
| YTD return | +58.09% | +154.74% |
| 1-year return | +155.57% | +226.63% |
| 5-year return | +121.14% | +60.87% |
| EPS (TTM) | $-1.85 | $-0.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $62.38M |
| Revenue growth (YoY) | — | +48.29% |
| Net income (latest FY) | $-167.79M | $-101.59M |
| Operating margin | — | -178.39% |
| Net margin | — | -162.85% |
| 52-week high | $48.51 | $34.39 |
| 52-week low | $14.25 | $6.69 |
| Distance from 52-week high | -19.13% | -34.37% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +34.13% | +100.18% |
| Average volume | 1.34M | 2.65M |
| Shares outstanding | 108.60M | 168.61M |
| Employees | 127 | 137 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed EWTX by 71.1 percentage points over the past year.
- The two companies sit in different sectors: Edgewise Therapeutics in Healthcare and Tango Therapeutics in Health Care.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Healthcare · Biotechnology · 127 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
EWTX vs TNGX FAQ
Which is bigger, Edgewise Therapeutics or Tango Therapeutics?
Edgewise Therapeutics (EWTX) is larger, with a market capitalization of $4.26B compared with $3.81B for Tango Therapeutics (TNGX).
Which stock has performed better over the past year, EWTX or TNGX?
TNGX returned +226.63% over the past 12 months, compared with +155.57% for EWTX (price return, excluding dividends). Past performance does not predict future results.
Are Edgewise Therapeutics and Tango Therapeutics in the same industry?
No. Edgewise Therapeutics is in the Healthcare sector, while Tango Therapeutics is in Health Care.